http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Oct 2025 23:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/Press+Releases/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 22, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food &amp; Drug Administration</span> (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease).</p> http://www.streetinsider.com/PRNewswire/FDA+Grants+Fast+Track+Designation+for+AJ201%2C+a+First-in-Class+Therapy+for+Kenndy%27s+Disease/25490024.html Wed, 22 Oct 2025 23:18:00 -0400 7754 A.06822034 O.20026344 O.22472222 http://www.streetinsider.com/Press+Releases/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 13, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the <span>World Muscle Society</span> (WMS) 2025 <span>International Congress</span> in <location value="LU/at..vienna" idsrc="xmltag.org" >Vienna</location>. http://www.streetinsider.com/Press+Releases/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html Mon, 13 Oct 2025 03:06:00 -0400 7754 O.22472222 http://www.streetinsider.com/Press+Releases/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 13, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the <span>World Muscle Society</span> (WMS) 2025 <span>International Congress</span> in <location value="LU/at..vienna" idsrc="xmltag.org" >Vienna</location>. http://www.streetinsider.com/Press+Releases/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html Mon, 13 Oct 2025 03:06:00 -0400 7754 O.22472222 http://www.streetinsider.com/PRNewswire/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 13, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the <span>World Muscle Society</span> (WMS) 2025 <span>International Congress</span> in <location value="LU/at..vienna" idsrc="xmltag.org" >Vienna</location>. http://www.streetinsider.com/PRNewswire/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html Mon, 13 Oct 2025 03:06:00 -0400 7754 O.22472222 http://www.streetinsider.com/PRNewswire/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Oct. 13, 2025</chron></span> /PRNewswire/ -- <span value="Gretai:7754" idsrc="xmltag.org" >AnnJi Pharmaceutical Co., Ltd.</span> (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the <span>World Muscle Society</span> (WMS) 2025 <span>International Congress</span> in <location value="LU/at..vienna" idsrc="xmltag.org" >Vienna</location>. http://www.streetinsider.com/PRNewswire/AnnJi+Showcases+Clinical+Breakthrough+of+AJ201+at+WMS+2025/25446365.html Mon, 13 Oct 2025 03:06:00 -0400 7754 O.22472222